This company listing is no longer active
A3E19Y Stock Overview
A commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MDxHealth SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.08 |
| 52 Week High | US$6.63 |
| 52 Week Low | US$1.76 |
| Beta | 0.79 |
| 11 Month Change | 9.26% |
| 3 Month Change | 33.12% |
| 1 Year Change | -50.16% |
| 33 Year Change | -64.61% |
| 5 Year Change | -81.74% |
| Change since IPO | -91.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| A3E19Y | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.3% | -0.7% | -0.02% |
| 1Y | -50.2% | -17.2% | 8.2% |
Return vs Industry: A3E19Y underperformed the German Biotechs industry which returned -23.3% over the past year.
Return vs Market: A3E19Y underperformed the German Market which returned 10% over the past year.
Price Volatility
| A3E19Y volatility | |
|---|---|
| A3E19Y Average Weekly Movement | 240.1% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: A3E19Y's share price has been volatile over the past 3 months.
Volatility Over Time: A3E19Y's weekly volatility has increased from 120% to 240% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 255 | Mike McGarrity | mdxhealth.com |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
MDxHealth SA Fundamentals Summary
| A3E19Y fundamental statistics | |
|---|---|
| Market cap | €85.52m |
| Earnings (TTM) | -€40.83m |
| Revenue (TTM) | €58.02m |
1.5x
P/S Ratio-2.1x
P/E RatioIs A3E19Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A3E19Y income statement (TTM) | |
|---|---|
| Revenue | US$63.69m |
| Cost of Revenue | US$25.20m |
| Gross Profit | US$38.48m |
| Other Expenses | US$83.30m |
| Earnings | -US$44.82m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.64 |
| Gross Margin | 60.42% |
| Net Profit Margin | -70.37% |
| Debt/Equity Ratio | 201.8% |
How did A3E19Y perform over the long term?
See historical performance and comparison